Biographies

Dr. Isa Odidi, Ph.D., is Chairman of the Board, Chief Executive Officer of Intellipharmaceutics International Inc. He was a co-founder, and has been an officer and/or a director of the Company or its predecessors since 1998. From 1995 to 1998, Dr. Odidi held positions, first as Director, then as Vice President of Research of Drug Development and New Technologies, at Biovail Corporation International (since merged into Valeant Pharmaceuticals International, Inc.), a drug delivery company. Prior to 1995, Dr. Isa Odidi held senior positions in academia and in the pharmaceutical and health care industries. He currently holds a Chair as Professor of Pharmaceutical Technology at the Toronto Institute of Pharmaceutical Technology in Canada, and is an Adjunct Professor at the Institute for Molecular Medicine in California. Dr. Odidi received his B.Sc. degree in Pharmacy, and his M.Sc. in Pharmaceutical Technology and his Ph.D. in Pharmaceutics from the University of London. Dr. Odidi is also a graduate of the Ivey Executive Management Program from Ivey School of Business, and obtained his MBA from the Rotman School of Management at the University of Toronto.

Dr. Amina Odidi, Ph.D., is President, Chief Operating Officer, Director of Intellipharmaceutics International Inc. She was a co-founder, and has been an officer and/or a director of the Company or its predecessors since 1998. She has extensive experience developing and applying proprietary technologies to the development of controlled-release drug products for third-party pharmaceutical companies. She has invented or co-invented various proprietary controlled delivery devices for the delivery of pharmaceutical, nutriceutical, biological, agricultural and chemical agents. Previously she has worked for the pharmaceutical and health care industry. She has coauthored articles, papers and textbooks. She received her B.Sc. in Pharmacy, M.Sc. in Biopharmaceutics, and her Ph.D. in Pharmaceutics from the University of London.

Mr. Andrew Patient has been appointed as Chief Financial Officer of the Company with effective from September 6, 2017. Mr. Patient has more than 20 years' experience with both Nasdaq- and TSX-listed companies, and has deep expertise in all facets of business, including operations, trade, finance, regulatory and business development, both nationally and internationally. In December 2011, Mr. Patient became CFO at Merus Labs International Inc., a Nasdaq and TSX dual-listed specialty pharmaceutical company that owns, markets and distributes prescription medications. During a five-year period, Mr. Patient helped grow Merus from a one-drug domestic platform to a 12-drug, 36 country international platform. At Merus, Mr. Patient oversaw several significant acquisitions, and implemented a low-cost operating model with a light infrastructure footprint. Mr. Patient was responsible for all accounting, finance and treasury functions, including external regulatory reporting, investor relations, and negotiating and executing key agreements for distribution and sales of products. Mr. Patient has been a Chartered Accountant (C.A.) since 1995.

Mr. John N. Allport is Vice President - Legal Affairs and Licensing, Secretary, Director of Intellipharmaceutics International Inc. He has been an officer and/or a director of the Company or its predecessors since 1998. Mr. Allport has in excess of twenty years' experience in the field of intellectual property law as a litigator with the international IP firm Sim Lowman Ashton & McKay LLP of Toronto, acting for and against many Fortune 500 companies. In that position, he also assisted in the creation and exploitation of the extensive IP licensing interests of such international licensing giants as Walt Disney Corporation, the Canadian Olympic Association and the World Wildlife Fund.

Dr. Patrick N. Yat, Ph.D., is Vice President - Pharmaceutical Analysis and Chemistry of IntelliPharmaCeutics International Inc. He serves as Vice President - Pharmaceutical Analysis and Chemistry from October 2009.

Mr. Kenneth Keirstead is Independent Director of Intellipharmaceutics International Inc. Mr. Keirstead is Executive Manager of the Lyceum Group, a consulting business. He was President and CEO, Sanofi Winthrop Canada Inc.; General Manager, Squibb Medical Systems International; President, Chemfet International and President, Quinton Instruments among other positions. Mr. Keirstead has published studies and reports on health care and related services topics.

Mr. Bahadur Madhani is Independent Director of Intellipharmaceutics International Inc. Mr. Madhani is President and CEO of Equiprop Management Limited, a consulting business. He is currently Chair of YMCA Canada. He was previously a member of the advisory board of Quebecor Ontario. Mr. Madhani has also served as former Chairman of United Way of Toronto, former Chair of the YMCA of Greater Toronto, former Chair of the Nelson Mandela Children's Fund of Canada., former Vice-Chair of YMCA Canada and former Chair, Toronto Grants Review Team of the Ontario Trillium Foundation. He was awarded membership in the Order of Canada in 2001.

Dr. Eldon R. Smith, M.D., is Independent Director of Intellipharmaceutics International Inc. Dr. Smith is President and CEO of Eldon R. Smith and Associates Ltd., a consulting business, and professor emeritus at the University of Calgary, Faculty of Medicine, where he served as the Dean of the Faculty of Medicine subsequent to being Head of the Department of Medicine and the Division of Cardiology. He is currently on the board of Alberta Health Services. Dr. Smith is past President of the Canadian Cardiovascular Society and served as Chairman of the Scientific Review Committee of the Heart and Stroke Foundation of Canada. Dr. Smith was appointed as an Officer of the Order of Canada in November 2005.

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: